PDS Biotechnology (PDSB) Appoints Kirk V. Shepard as Chief Medical Officer Jan 22, 2024 04:46PM
PDS Biotechnology (PDSB) Appoints Kirk V. Shepard as Chief Medical Officer Jan 22, 2024 04:46PM
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer Jan 22, 2024 04:45PM
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference Jan 16, 2024 08:00AM
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Dec 4, 2023 04:50PM
View Older Stories

Nov 28, 2023 07:31AM PDS Biotechnology (PDSB) Appoints Lars Boesgaard as Chief Financial Officer
Nov 28, 2023 07:30AM PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
Nov 14, 2023 07:30AM PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 9, 2023 08:03AM PDS Biotechnology (PDSB) Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy
Nov 9, 2023 08:00AM PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Na
Nov 7, 2023 08:00AM PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
Oct 23, 2023 08:07AM PDS Biotechnology (PDSB) Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
Oct 23, 2023 08:00AM PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
Oct 11, 2023 08:02AM PDS Biotechnology (PDSB) Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial of PDS0301
Oct 11, 2023 08:00AM PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
Oct 3, 2023 07:01AM PDS Biotechnology (PDSB) Reports Interim 24-Month Survival Rate of 74% with PDS0101 in Combination with KEYTRUDA
Oct 3, 2023 07:00AM PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)
Oct 2, 2023 08:00AM PDS Biotechnology (PDSB) Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA
Oct 2, 2023 08:00AM PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
Sep 26, 2023 08:00AM PDS Biotech to Present at the LD Micro Main Event XVI
Sep 25, 2023 08:00AM PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
Sep 20, 2023 04:05PM PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
Sep 20, 2023 08:02AM PDS Biotechnology (PDSB) Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
Sep 20, 2023 08:00AM PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
Sep 13, 2023 08:00AM PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
Sep 6, 2023 04:05PM PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
Sep 6, 2023 08:00AM PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
Aug 16, 2023 08:00AM PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting
Aug 14, 2023 07:30AM PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 14, 2023 07:02AM PDS Biotechnology (PDSB) Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
Aug 14, 2023 07:00AM PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
Aug 7, 2023 08:00AM PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
Aug 2, 2023 08:00AM PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023
Jul 25, 2023 08:00AM PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023
Jul 17, 2023 08:00AM PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023
Jul 11, 2023 08:00AM PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301
Jun 20, 2023 08:00AM PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
Jun 14, 2023 08:00AM PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer
Jun 5, 2023 02:52PM PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
May 25, 2023 05:04PM PDS Biotechnology (PDSB) Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA for Head and Neck Cancer Patients
May 25, 2023 05:00PM PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
May 18, 2023 08:00AM PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
May 15, 2023 07:30AM PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results
May 4, 2023 08:00AM PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
Apr 27, 2023 08:00AM PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patie
Apr 24, 2023 08:02AM PDS Biotechnology (PDSB) Receives $1.4M After Selling Its Net Operating Loss Tax Benefits
Apr 24, 2023 08:00AM PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
Apr 12, 2023 08:00AM PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023
Apr 3, 2023 08:00AM PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
Mar 30, 2023 08:02AM PDS Biotechnology (PDSB) Plans to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA
Mar 30, 2023 08:00AM PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
Mar 29, 2023 07:30AM PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium 
Mar 28, 2023 07:30AM PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results
Mar 16, 2023 08:00AM PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results
Mar 7, 2023 08:00AM PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference
View Older Stories